mRNA-1653 Vaccine Description
mRNA-1653 is a combination vaccine that consists of two distinct mRNA sequences encoding the fusion (F) proteins of hMPV and PIV3 formulated in Moderna’s proprietary lipid nanoparticle (LNP) technology.
mRNA-1653 Vaccine Indication
mRNA-1653 is designed to protect against human metapneumovirus (hMPV) and parainfluenza type 3 (PIV3), two viruses that cause respiratory infections.
mRNA-1653 Vaccine News
September 17, 2020 - Moderna reported the First 10 pediatric patients dosed in Phase 1 study of hMPV/PIV3 vaccine (mRNA-1653). Sites have re-opened and are actively recruiting participants. Moderna owns worldwide commercial rights to mRNA-1653.
mRNA-1653 Vaccine Clinical Trials
Clinical Trial NCT03392389: Safety, Reactogenicity, and Immunogenicity of mRNA-1653 in Healthy Adults
- This clinical study will assess the safety, reactogenicity, and immunogenicity of mRNA-1653, a combined human metapneumovirus and human parainfluenza virus type 3 vaccine in healthy adults.